CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has been effective faithfully but unsuccessfully to produce an one-time therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix.

In development of this particular treatment, CytoDyn has cast its net far and wide both geographically and in terminology of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they will actually be being used is actually an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as being a combination therapy in the curing of multi-drug-resistant HIV happen to be closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of my past few shares. The 1st CytoDyn article of mine, “CytoDyn: What In order to Do When It’s Too Good to be able to Be True?”, set out the following prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan presented such a very marketing image in the Uptick Newswire interview that I came away with an inadequate impression of the company.

Irony of irony, my poor opinion of the business enterprise has grown steadily, yet the disappointment hasn’t been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > 6 bagger at the moment still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much-storied therapy (which I shall refer to as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor of the therapy as well as prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s transaction of $3.5 million transfers ownership of this technology as well as connected intellectual property from Progenics to CytoDyn, and roughly twenty five million mg of bulk drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 million) plus the very first brand new drug program endorsement ($5 million), and also royalty payments of five % of net sales after commercialization.

Since that moment, CytoDyn’s leading nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to buy a market place cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous indications and numerous therapies, it’s this single therapies as well as a “broad pipeline of indications” because it puts it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a potentially beneficial therapy of dozens of indications.

Its opening banner on its website (below) shows an active business with diverse interests albeit focused on leronlimab, several disease sorts, multiple publications in addition to multiple presentations.

Can it all be smoke and mirrors? That’s a question I’ve been asking myself through the really start of my interest in this particular organization. Judging by way of the multiples of a huge number of diverse remarks on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m much from alone in this particular question.

CytoDyn is a traditional battleground, or maybe some might say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News